Since Feb 25, 2011
Therapeutics Antibody Characterization
27 261
Thu January 21st, 2016
Antibody Drug Conjugates Therapy:Treatment of Cancer Patients
The market for antibody drug conjugate is in infancy stage. So far, only three antibody drug conjugates have received market approval from the U.S. Food and Drug Administration (FDA). However, the first among them, Mylotarg was withdrawn from the market by its manufacturer Wyeth, Inc., group company of Pfizer, Inc. in June 2010. Myotarg was used to treat acute myelogenous leukemia but a clinical trial showed that the drug has accelerated the mortality rate among the myelogenous leukemia patients and had added no benefits over conventional cancer therapies. Therefore, the market for antibody drug conjugates can be segmented on the basis of other two approved drugs which include: Adcertis Kadcyla Read More:
1 1 51

Want to join the conversation? Login or Register!